Home › Skin Conditions › NCT00842283
Role of Angiogenesis in Dermatologic Diseases: A Potential Therapeutic Target
Who can join
Ages 16 and older · All sexes · Healthy volunteers welcome
Full eligibility criteria
Inclusion Criteria: * 16 years of age or older. * willing to have a skin biopsy Exclusion Criteria: * under 16 years of age * unable to carry out instructions
About the study
The researchers believe that pro-angiogenic factors are upregulated in a wide range of dermatologic diseases, including port wine stains, hemangiomas, angiofibromas, Kaposi's sarcoma, angiosarcoma, scars, rosacea, and psoriasis. Select specimens may undergo genetic analysis to investigate underlying molecular pathways associated with dysregulated angiogenesis in cutaneous disease.
Biospecimens, either previously obtained or newly collected from dermatologic conditions, will be analyzed for angiogenic markers. Discarded skin tissue from surgical or biopsy procedures may also be used, including both diseased and non-diseased tissue from the same donor. Some specimens may also undergo genetic analysis to investigate underlying molecular pathways.
De-identified data such as age, sex, race, cause of death, lesion location, and description will be recorded. Currently, specimens are limited to clinically diagnosed lesions not typically biopsied, or lesions already confirmed by prior biopsy.
What is being tested
- skin tissue sample (other)
Sponsor: University of California, Irvine · Participants: 85 · Started: 2008-11
Contact the study team
- Hanna Kim · Phone: 949-824-2251
Official record on ClinicalTrials.gov — NCT00842283
Locations in the U.S.
| California | Beckman Laser Institute and Medical Clinic, Irvine Dermatology Clinic at Gavin Herbert Eye Institute, Irvine |
Conditions
From ClinicalTrials.gov, data retrieved Oct 1, 2026. Each study sets its own eligibility; the study team decides who can join.